stockrowHims & Hers Health, Inc.
HIMS Healthcare Drug Manufacturers Specialty & Generic
Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024.
- Revenue
- +38.3%
- EPS
- −294.7%
- Free cash flow
- +5.09%
- Total debt
- +40.8%
Quarter to June 2026, against a year earlier
Follow HIMS
Alert me
Hims & Hers Health, Inc. (HIMS) EV/FCF
As of 5 November 2026, Hims & Hers Health, Inc. (HIMS) trades at a EV/FCF of 73.6×. Over the past ten years it has ranged from −2,587× (May 2023) to 113× (January 2026); the current reading is higher than 84% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 104× | 342.78% |
| FY2024 | 23.5× | (26.51%) |
| FY2023 | 32.0× | — |
| FY2022 | −38.2× | — |
| FY2022 | −28.9× | — |
| FY2021 | −27.8× | — |
| FY2021 | −108× | — |
| FY2020 | −98.7× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2026 | 103× | 65.53% |
| Mar 2026 | 62.3× | (40.18%) |
| Dec 2025 | 104× | 5.77% |
| Sep 2025 | 98.4× | 18.34% |
| 22 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | −158× |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −21.7× |
| LNTH Lantheus Holdings, Inc. compare | 16.6× |
| LQDA Liquidia Corporation compare | 25.6× |
| KNSA Kiniksa Pharmaceuticals International, plc compare | 32.2× |
| ALKS Alkermes plc compare | 36.0× |
| HIMS Hims & Hers Health, Inc. | 73.6× |
| RDY Dr. Reddy's Laboratories Ltd compare | 126× |
| SUPN Indivior Pharmaceuticals Inc. compare | 138× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on HIMS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement